216 related articles for article (PubMed ID: 25492523)
1. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits.
Regester LE; Chmiel JD; Holler JM; Vorce SP; Levine B; Bosy TZ
J Anal Toxicol; 2015 Mar; 39(2):144-51. PubMed ID: 25492523
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.
Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD
Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345
[TBL] [Abstract][Full Text] [Related]
3. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays.
Begeman A; Franssen EJF
Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays.
Swortwood MJ; Hearn WL; DeCaprio AP
Drug Test Anal; 2014; 6(7-8):716-27. PubMed ID: 23677923
[TBL] [Abstract][Full Text] [Related]
5. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
Pettersson Bergstrand M; Helander A; Hansson T; Beck O
Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of commercial multi-drug oral fluid devices to identify 39 new amphetamine-designer drugs.
Nieddu M; Burrai L; Trignano C; Boatto G
Leg Med (Tokyo); 2014 Mar; 16(2):106-9. PubMed ID: 24360925
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine.
DeRienz RT; Holler JM; Manos ME; Jemionek J; Past MR
J Anal Toxicol; 2008; 32(6):433-7. PubMed ID: 18652750
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement.
Nakanishi K; Miki A; Zaitsu K; Kamata H; Shima N; Kamata T; Katagi M; Tatsuno M; Tsuchihashi H; Suzuki K
Forensic Sci Int; 2012 Apr; 217(1-3):174-81. PubMed ID: 22154438
[TBL] [Abstract][Full Text] [Related]
9. Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamine and methamphetamine.
Apollonio LG; Whittall IR; Pianca DJ; Kyd JM; Maher WA
J Anal Toxicol; 2007 May; 31(4):208-13. PubMed ID: 17555644
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of designer amphetamine interference in GC-MS amine confirmation procedures.
Holler JM; Vorce SP; Knittel JL; Malik-Wolf B; Levine B; Bosy TZ
J Anal Toxicol; 2014 Jun; 38(5):295-303. PubMed ID: 24687012
[TBL] [Abstract][Full Text] [Related]
11. Cross-reactivity of commercial immunoassays for screening of new amphetamine designer drugs. A review.
Nieddu M; Baralla E; Pasciu V; Rimoli MG; Boatto G
J Pharm Biomed Anal; 2022 Sep; 218():114868. PubMed ID: 35688007
[TBL] [Abstract][Full Text] [Related]
12. Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse.
Beck O; Rausberg L; Al-Saffar Y; Villen T; Karlsson L; Hansson T; Helander A
Drug Test Anal; 2014 May; 6(5):492-9. PubMed ID: 24665024
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamines.
Kerrigan S; Mellon MB; Banuelos S; Arndt C
J Anal Toxicol; 2011 Sep; 35(7):444-51. PubMed ID: 21871153
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of five immunoassays for the determination of digoxin in serum.
Sasieta M; Jimeno P
Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):935-40. PubMed ID: 8960471
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three commercial amphetamine immunoassays for detection of methamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, and methylenedioxyethylamphetamine.
Ruangyuttikarn W; Moody DE
J Anal Toxicol; 1988; 12(4):229-33. PubMed ID: 2903272
[TBL] [Abstract][Full Text] [Related]
16. ELISA Detection of 30 New Amphetamine Designer Drugs in Whole Blood, Urine and Oral Fluid using Neogen® "Amphetamine" and "Methamphetamine/MDMA" Kits.
Nieddu M; Burrai L; Baralla E; Pasciu V; Varoni MV; Briguglio I; Demontis MP; Boatto G
J Anal Toxicol; 2016 Sep; 40(7):492-7. PubMed ID: 27405364
[TBL] [Abstract][Full Text] [Related]
17. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening.
Armbruster DA; Hubster EC; Kaufman MS; Ramon MK
Clin Chem; 1995 Jan; 41(1):92-8. PubMed ID: 7813088
[TBL] [Abstract][Full Text] [Related]
18. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
Peters FT; Schaefer S; Staack RF; Kraemer T; Maurer HH
J Mass Spectrom; 2003 Jun; 38(6):659-76. PubMed ID: 12827635
[TBL] [Abstract][Full Text] [Related]
19. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
Mina A
J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
[TBL] [Abstract][Full Text] [Related]
20. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum.
Wohlfarth A; Weinmann W; Dresen S
Anal Bioanal Chem; 2010 Apr; 396(7):2403-14. PubMed ID: 20069283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
